In 2003, the ACOG/SMFM endorsed IM progesterone for PTB prevention. But new data has called this into question (PROLONG trial). In this session, we will review the PROLONG data and compare it to the newly released EPPPIC study. What does the ACOG now recommend? We will answer these questions and more in this session.